Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial.

MLA

Fine, Nowell M., et al. “Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial.” The Canadian Journal of Cardiology, vol. 40, no. 4, Apr. 2024, pp. 659–61. EBSCOhost, https://doi.org/10.1016/j.cjca.2023.11.017.

APA

Fine, N. M., Litwin, O., Kent, W. D. T., Holloway, D. D., Roy, J., Miller, R. J. H., Chih, S., Davey, R. A., Isaac, D. L., Sharma, N., Lyons, K. J., & Howlett, J. G. (2024). Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial. The Canadian Journal of Cardiology, 40(4), 659–661. https://doi.org/10.1016/j.cjca.2023.11.017

Chicago

Fine, Nowell M, Owen Litwin, William D T Kent, Daniel D Holloway, Jill Roy, Robert J H Miller, Sharon Chih, et al. 2024. “Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial.” The Canadian Journal of Cardiology 40 (4): 659–61. doi:10.1016/j.cjca.2023.11.017.